Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Vectura Group (VEC) Ord 0.0271p

Sell:113.00p Buy:113.60p 0 Change: 0.60p (0.54%)
FTSE 250:1.11%
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:113.00p
Buy:113.60p
Change: 0.60p (0.54%)
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:113.00p
Buy:113.60p
Change: 0.60p (0.54%)
Market closed Prices as at close on 25 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Contact details

Address:
Unit 1, Prospect West, Bumpers Way
CHIPPENHAM
SN14 6FH
United Kingdom
Telephone:
+44 (01249) 667700
Website:
www.vectura.com

Important dates

Future events
There are no future events available.
Past events
Interim results 15 September 2020 15/09/20
Trading Announcement 27 May 2020 27/05/20
AGM 27 May 2020 27/05/20
Annual report 20 April 2020 20/04/20
Final results 17 March 2020 17/03/20
Trading Announcement 13 January 2020 13/01/20

General stock information

EPIC:
VEC
ISIN:
GB00BKM2MW97
Market cap:
£670.96 million
Shares in issue:
595.88 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE techMARK 100,FTSE 250,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • William Downie
    Chief Executive Officer, Executive Director
  • Paul Fry
    Chief Financial Officer, Executive Director
  • Joanne Hombal
    Executive Vice President of Human Resources
  • Antony Fitzpatrick
    Executive Vice President – Operations
  • Sharon Johnson
    Executive Vice President - Delivery Management
  • David Lescuyer
    Executive Vice President – Oral Business
  • Christina Olsen
    Executive Vice President - Corporate Strategy and Communications
  • Geraldine Venthoye
    Executive Vice President - Pharmaceutical Development
  • John Murphy
    General Counsel, Company Secretary
  • Mark Bridgewater
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.